Anchel González-Barriga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anchel González-Barriga has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Arturo López-Castel
Human Translational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Av. Vicent Andrés Estellés, 19, Valencia 46100, Spain; INCLIVA Biomedical Research Institute, Av. Menendez Pelayo 4, Valencia 46010, Spain; Ciberer Isciii, Av. Monforte de Lemos 3-5, Madrid 28029, Spain
1 shared publication - Jorge Espinosa-Espinosa
Translational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Spain
1 shared publication - Ruben Artero
University of Valencia
1 shared publication
Latest Publications
- Open Access
- 27 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1441
Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies
Omics studies are crucial to improve our understanding of myotonic dystrophy type 1 (DM1), the most common muscular dystrophy in adults. Employing tissue samples and cell lines derived from patients and animal models, omics approaches have revealed the myriad alterations in gene and microRNA expression, alternative splicing, 3′ polyadenylation, CpG methylation, and proteins levels, among others, that contribute to this complex multisystem disease. In addition, omics characterization of drug candidate treatment experiments provides crucial insight into the degree of therapeutic rescue and off-target effects that can be achieved. Finally, several innovative technologies such as single-cell sequencing and artificial intelligence will have a significant impact on future DM1 research.
- 27 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1441
Open AccessDeciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies
Omics studies are crucial to improve our understanding of myotonic dystrophy type 1 (DM1), the most common muscular dystrophy in adults. Employing tissue samples and cell lines derived from patients and animal models, omics approaches have revealed the myriad alterations in gene and microRNA expression, alternative splicing, 3′ polyadenylation, CpG methylation, and proteins levels, among others, that contribute to this complex multisystem disease. In addition, omics characterization of drug candidate treatment experiments provides crucial insight into the degree of therapeutic rescue and off-target effects that can be achieved. Finally, several innovative technologies such as single-cell sequencing and artificial intelligence will have a significant impact on future DM1 research.